Jazz Pharmaceuticals PLC at RBC Capital Markets Healthcare Conference Transcript
My name is Randall Stanicky, I come from the Specialty Pharmaceuticals Sectors here at RBC Capital Markets. I'm pleased to have our next presentation. We have Matt Young, the Chief Financial Officer; and Mike Miller, who heads up Commercial for Jazz Pharmaceuticals.
Questions & Answers
You guys have a lot going on, Sunosi just approved, JZP-258 data out and a lot to talk about here. But I want to throw out a bigger picture question that probably kicks off maybe a larger discussion. And Matt, I think you probably know where I'm going maybe with this. There's been a lot of focus on Vyxeos the move to HemOnc, growing out that platform, the need to diversify away from Xyrem. I think most can step back and say, we'd hoped Vyxeos might have wrapped a bit quicker. And so let me just throw this question to, you to begin with, do we need
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |